A single-arm, open-label, phase 2 study of nab-paclitaxel and carboplatin chemotherapy plus necitumumab in the first-line treatment of patients with stage IV squamous non-small cell lung cancer (NSCLC)

Date

08 Oct 2016

Session

Poster Display

Presenters

Mark Socinski

Citation

Annals of Oncology (2016) 27 (6): 416-454. 10.1093/annonc/mdw383

Authors

M. Socinski1, M. Gil2, J. Shahidi3, G.Y. Chao4, L. Villaruz1

Author affiliations

  • 1 Medical Oncology, University of Pittsburgh UPMC Cancer Pavilion, PA 15232 - Pittsburgh/US
  • 2 Oncology, Eli Lilly Polska, Warsaw/PL
  • 3 Oncology, Eli Lilly and Company, Indianapolis/US
  • 4 Biostatistics, Eli Lilly and Company, Indianapolis/US
More

Resources

Background

Necitumumab (neci), a human IgG1-type monoclonal antibody directed against the EGFR has recently been found to significantly improve outcomes in patients with Stage IV squamous NSCLC when combined with gemcitabine/cisplatin. These data coupled with the efficacy and safety advantages of nab-paclitaxel (nab-pac) over solvent-based paclitaxel provide a strong rationale for the investigation of neci in combination with nab-pac as first-line therapy in Stage IV squamous NSCLC.

Trial design

JFCP (NCT02392507) is a single-arm, open-label, Phase 2 study being conducted to evaluate the effectiveness and safety and tolerability of nab-pac and carboplatin plus neci as first-line therapy in patients with Stage IV squamous NSCLC (life expectancy ≥12 weeks; ECOG PS ≤1; tumor tissue availability for immunohistochemistry analysis). Study therapy consists of an induction (triplet) regimen of nab-pac (100 mg/m2 IV on Days 1, 8, and 15) and carboplatin (AUC 6 mg.min/mL IV on Day 1) plus neci (800 mg absolute dose IV on Days 1 and 8) administered for a maximum of 4 cycles (or until radiographic documentation of progressive disease, toxicity requiring cessation, protocol noncompliance, or withdrawal of consent). Patients with a response of stable disease or better, assessed radiographically, after 4 cycles of induction regimen are eligible to receive the maintenance (doublet) regimen of neci (800 mg on Days 1and 8) plus nab-pac (100 mg/m2 on Days 1 and 8) every 3 weeks until disease progression occurs or other discontinuation criteria are met. The primary endpoint of this study is the best objective response rate (ORR); key secondary endpoints include PFS, OS, and DCR. Efficacy analyses for ORR and DCR will be performed for qualified patients (received any amount of study drug and had a complete radiographic assessment at baseline). Patients surviving for ≥8 weeks after first dose and with no post-baseline radiographic assessment will be disqualified. Efficacy analyses for PFS and OS will be performed for all patients who have received any amount of study drug. Enrollment began October 2015; planned enrollment is 50 patients.

Clinical trial identification

ClinicalTrails.gov identifier: NCT02392507

Legal entity responsible for the study

Eli Lilly and Company

Funding

Eli Lilly and Company

Disclosure

M. Socinski: Research Support: Lilly and Celgene Speaker's Bureau: Celgene. M. Gil, J. Shahidi, G.Y. Chao: Employee of Eli Lilly and Company. All other authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings